9th International Symposium

Haploidentical Stem Cell Transplantation

Pro

gra

m

28-29 January, 2018 The David Lopatie Conference Centre Weizmann Institute of Science, Israel

Sunday January 2808:30 Gathering and coffee

09:00 Opening Session Greetings by Prof. Daniel Zaifman President, Weizmann Institute of Science Prof. Steffen Jung, head of Immunology and Prof. Yair Reisner

09:20-11:00 Optimizing T cell depleted ‘Megadose’ Haploidentical Transplants Moderators: Amos Toren and Avichai Shimoni

In children09:20 Rupert Handgretinger (Tübingen) Update on TcRalpha/beta depletion

09:35 Franco Locatelli (Rome) Alpha/beta T-cell depleted haplo-HSCT and adoptive infusion of geneti-cally-modified donor cells to accelerate immune recovery

09:50 Peter Lung (Tübingen) Final results of Tubingen CD3/19 trial

In adults10:05 Franco Aversa (Parma) The Alfa-Beta T cell depletion platform for HaploHSCT in adults with

malignant hematologic disorders

10:20 Massimo Martelli (Perugia) The ultimate haplo transplant for the elderly with acute leukemia

10:35 Yair Reisner (Rehovot) Towards safer haploidnetical magadose HSCT

10:50 Discussion

11:00 Coffee Break

11:15-12:55 Optimizing T cell replete Haploidentical Transplants Moderators: Stefan Ciurea and Tsila Zukerman

G-CSF-primed BM11:15 Huang Xiao-Jun (Beijing) Is HLA-matched sibling donor transplant always better than

haploidentical allograft?

11:30 William Arcese (Rome) Haploidentical, unmanipulated, G-CSF primed Bone Marrow Transplantation, after uniform conditioning regimen: a long-term follow up

PT-CY11:45 Rick Jones (Baltimore) The development of post-transplant cyclophosphamide: 50 years of

translational team science

12:00 Dick Champlin (Houston) Considerations for haploidentical vs. unrelated donor transplants

12:15 Andrea Bacigalupo (Rome) Does timing of PTCY matter?

12:30 Arnon Nagler ( Tel-Aviv) Haploidentical Transplantation: the ALWP Experience

12:45 Discussion

12:55 Lunch

14:00-14:40 Gene transfer Vs Haplo HSCT in Non-malignant Diseases Moderators: Itzhak Ben-Bassat and Moshe Yeshurun

14:00 Marina Cavazanna (Paris) Advances of gene therapy for inherited diseases

14:15 Pietro Sodani (Rome) Long term outcome of haploidentical transplants inhemoglobinopathies diseases

14:30 Discussion

14:30-15:50 Stem Cell Biology and Thymic Reconstitution Moderators: Liran Shlush and Raz Somech

14:40 Tsvee Lapidot (Rehovot) Metabolic regulation of blood and bone forming stem cells:The role of ROS and nitric oxide

14:55 Loredana Rugerri (Perugia) How alloreactive natural killer cells accelerate immune reconstitution

15:10 Kobi Abramson (Rehovot) induction of self-tolerance in the thymus

15:25 Marcel Van-den-Brink (New York) Strategies to enhance post-transplant immune reconstitution

15:40 Discussion

Monday January 2908:30-10:40 Adoptive Transfer of Immunity Moderators: Shai Izraeli and Yair Reisner

08:30 Hermann Einsele (Wurzburg) The use of bispecific antibodies to optimize the outcome of patients with acute leukemia and multiple myeloma after SCT

08:45 Warren Shlomchick (Seattle) Minor histocompatibility specific T cells for engraftment with low intensity conditioning without GVHD

09:00 Richard O’Reilly (New York) Treatment of viral diseases post transplant with banked third party-derived virus-specific T-cells selected for HLA restriction

09:15 Fabio Ciceri (Milano) HSV-TK suicide gene engineered donor T-cells infusions

09:30 Malcolm Brenner (Houston) Making "Triple-Threat-T cells" for Haploidentical transplant recipients

09:45 Stephan Mielke (Stockholm) Selective Allodepletion with ATIR(TM): An immunotherapeutic platform goes randomized phase III

10:00 Matthias Eyrich (Wurzburg) Therapeutic vaccine strategies to induce tumor-specificT-cell responses

10:15 Elizabeth Shpall (Houston) Cord blood derived transplantation and cellular therapy for the future

10:30 Discussion

10:40 Coffee Break

11:00-11:55 Adoptive Transfer of Regulatory Cells Moderators: Robert Parkman and Yitzhak Yaniv

11:00 Rob Negrin (Stanford) Immune regulatory strategies to control GVHD

11:15 Andrea Velardi (Perugia) T regs for safer cellular immunotherapy of leukaemia after megadose haplo HSCT

11:30 Wim Fibbe (Leiden) Harnessing mesenchymal stromal cells for immune regulatory treatment

11:45 Discussion

11:55 Lunch

12:55-14:10 Immune Tolerance and Organ Transplantation Moderators: Alex Yusim and Herman Waldmann

12:55 Herman Waldmann (Oxfrod) Aiming for therapeutic tolerance

13:10 Maria Grazia Roncarolo (Stanford) Next generation T regulatory cell-based immunotherapies

13:25 Leo Luznik (Baltimore) PTCy and chimerism-based tolerance

13:40 Megan Sykes (New York) Transplantation tolerance in non-human primates and humans

13:55 Sam Strober (Stanford) Prevention of kidney transplant rejection and mixed chimerism; safety and efficacy

14:10 Chava Rosen (Rehovot) Lung regeneration by transplantation of lung progenitors across MHC barriers: lessons from allogenic HSCT

14:25 Discussion

14:35 Coffee Break

14:50-16:30 CAR T cells and Checkpoint Inhibitors Moderators: Gidi Gross and Bob Gale

14:50 Zelig Eshhar (Rehovot) Double CAR for melanoma treatment

15:05 Carl June (Philadelphia) Engineering T cells and stem cells to generate anti-leukemic hematopoiesis

15:20 Stan Riddel (Seattle) Strategies for improving CAR T cell antitumor efficacy

15:35 Cameron Turtle (Seattle) Toxicities of CD19 CAR-T cell immunotherapy

15:50 Katy Rezvani (Houston) Engineering natural killer cells for cancer immunotherapy

16:05 Rob Soifer (Boston) Checkpoint inhibition after allogeneic transplantation

16:20 Discussion

16:30 Concluding Remarks

Chair Yair Reisner | Co-Chairs Massimo Martelli, Franco Aversa | Organizing committee Franco Aversa, Massimo Martelli, Yair Reisner, Hermann Einsele, Arnon Nagler More information & accessibility issues Dikla Kislev dikla.kislev@weizmann.ac.il

For registration please send an email to: hsct17@weizmann.ac.ilRegistration is free but mandatory, space is limited in the auditorium and on a first registered basis